Literature DB >> 34417569

Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently.

Zimo Yang1, Yonghui Sun1, Zhihao Ni1, Celi Yang2,3,4, Yan Tong1, Yujie Liu1, Haitao Li2,3,4, Yu Rao5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34417569      PMCID： PMC8648895          DOI： 10.1038/s41422-021-00533-6

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   46.297


× No keyword cloud information.
  14 in total

1.  Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.

Authors:  Jorge E Cortes; Brian A Jonas; Thorsten Graef; Ying Luan; Anthony S Stein
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-05-13

2.  Mechanism of auxin perception by the TIR1 ubiquitin ligase.

Authors:  Xu Tan; Luz Irina A Calderon-Villalobos; Michal Sharon; Changxue Zheng; Carol V Robinson; Mark Estelle; Ning Zheng
Journal:  Nature       Date:  2007-04-05       Impact factor: 49.962

3.  PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.

Authors:  Yonghui Sun; Xingwang Zhao; Ning Ding; Hongying Gao; Yue Wu; Yiqing Yang; Meng Zhao; Jinseok Hwang; Yuqin Song; Wanli Liu; Yu Rao
Journal:  Cell Res       Date:  2018-06-06       Impact factor: 25.617

4.  Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

Authors:  Jiuling Yang; Yangbing Li; Angelo Aguilar; Zhaomin Liu; Chao-Yie Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2019-10-21       Impact factor: 7.446

5.  Targeted protein degradation: expanding the toolbox.

Authors:  Matthieu Schapira; Matthew F Calabrese; Alex N Bullock; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2019-10-30       Impact factor: 84.694

6.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:  Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

7.  Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway.

Authors:  Céline Chauvin; Samia Salhi; Olivier Jean-Jean
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

8.  A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.

Authors:  Mary E Matyskiela; Gang Lu; Takumi Ito; Barbra Pagarigan; Chin-Chun Lu; Karen Miller; Wei Fang; Nai-Yu Wang; Derek Nguyen; Jack Houston; Gilles Carmel; Tam Tran; Mariko Riley; Lyn'Al Nosaka; Gabriel C Lander; Svetlana Gaidarova; Shuichan Xu; Alexander L Ruchelman; Hiroshi Handa; James Carmichael; Thomas O Daniel; Brian E Cathers; Antonia Lopez-Girona; Philip P Chamberlain
Journal:  Nature       Date:  2016-06-22       Impact factor: 49.962

9.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Authors:  Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

10.  Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.

Authors:  Tyler B Faust; Hojong Yoon; Radosław P Nowak; Katherine A Donovan; Zhengnian Li; Quan Cai; Nicholas A Eleuteri; Tinghu Zhang; Nathanael S Gray; Eric S Fischer
Journal:  Nat Chem Biol       Date:  2019-11-04       Impact factor: 15.040
View more
  5 in total

1.  PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Authors:  Xin Han; Wenyi Wei; Yi Sun
Journal:  Acta Mater Med       Date:  2022-05-31

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 3.  Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein-Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases.

Authors:  Fengzhi Li; Ieman A M Aljahdali; Xiang Ling
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

Review 4.  An overview of kinase downregulators and recent advances in discovery approaches.

Authors:  Beilei Wang; Hong Wu; Chen Hu; Haizhen Wang; Jing Liu; Wenchao Wang; Qingsong Liu
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 5.  Targeted protein degradation: mechanisms, strategies and application.

Authors:  Lin Zhao; Jia Zhao; Kunhong Zhong; Aiping Tong; Da Jia
Journal:  Signal Transduct Target Ther       Date:  2022-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.